Plasma levels of β2-microglobulin, a biomarker of peripheral arterial disease, are not affected by maximal leg exercise in patients with intermittent claudication

Atherosclerosis

Volumn 203, Issue 1, 2009, Pages 38-40

  Busti, Chiara ^a   Migliacci, Rino ^b   Falcinelli, Emanuela ^a   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Division of Internal Medicine   (Italy)

Author keywords

2 Microblogulin; Biomarker; Peripheral arterial disease

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; BLOOD LEVEL; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE SEVERITY; HUMAN; INTERMITTENT CLAUDICATION; LEG EXERCISE; LEG PAIN; LETTER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREADMILL EXERCISE;

AGED; ATHEROSCLEROSIS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; EXERCISE THERAPY; FEMALE; HUMANS; INFLAMMATION; INTERMITTENT CLAUDICATION; LEG; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROTEOMICS; TREATMENT OUTCOME;

EID: 60649092316     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.06.023     Document Type: Letter

References (13)

1. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1327
2. Golomb B.A., Dang T.T., and Criqui M.H. Peripheral arterial disease: morbidity and mortality implications. Circulation 114 (2006) 688-699
3. Hankey G.J., Norman P.E., and Eikelboom J.W. Medical treatment of peripheral arterial disease. JAMA 295 (2006) 547-553
4. White C. Clinical practice. Intermittent claudication. N Engl J Med 356 (2007) 1241-1250
5. TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 (2007) S5A-S67A
6. Arpegård J, Ostergren J, de Faire U, Hansson LO, Svensson P. Cystatin C-A marker of peripheral atherosclerotic disease? Atherosclerosis 2008 Jan 8 [Epub ahead of print].
7. Annex B.H. Is a simple biomarker for peripheral arterial disease on the horizon?. Circulation 116 (2007) 1346-1348
8. Shankar A., Li J., Nieto F.J., Klein B.E., and Klein R. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J 154 (2007) 495-501
9. Vidula H., Tian L., Liu K., et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 148 (2008) 85-93
10. Wilson A.M., Kimura E., Harada R.K., et al. B2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 116 (2007) 1396-1403
11. Shinkai S., Chaves P.H., Fujiwara Y., et al. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med 168 (2008) 200-206
12. Brevetti G, Piscione F, Cirillo P, et al. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis 2008 Feb 15 [Epub ahead of print].
13. Gresele P., Migliacci R., Procacci A., De Monte P., and Bonizzoni E. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 97 (2007) 444-450